3 reasons why I think NIB shares could still be a buy

NIB has a lot of things going for it.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Ltd (ASX: NHF) share price has had a rather successful year so far in 2023. Since the start of the year, NIB shares have risen a pleasing 9.07%, going from $7.61 each to Monday's market close price of $8.30. 

That compares favourably against the S&P/ASX 200 Index (ASX: XJO), which is up around 5.19% over the same period:

NIB shares are also up 13.85% over the past 12 months. 

But this ASX 200 insurance provider could still be worth a buy today, despite the gains the company has already booked over the past seven months or so. Here are three reasons why.

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,

Image source: Getty Images

3 reasons that NIB shares could still be a buy today

NIB shares: A major player in a government-supported industry

Most Australians would be at least somewhat familiar with private health insurance and its role in our healthcare system. NIB is a major provider of private health insurance services in Australia, with around a 9.4% market share.

Private health insurance is one of the few products that the government pushes customers into. If you earn above a certain income threshold, you could get penalised with extra tax bills if you don't hold an eligible policy.

Few companies can say that the government actively heard customers their way. But NIB can, making it a compelling reason to consider this company in my view.

A company with strong fundamentals

The best ASX shares tend to display an ability to grow revenue, earnings and profits at a compounding rate over time. NIB has shown it has what it takes to deliver in this arena. Its most recent half-yearly earnings report, covering the six months to 31 December 2022, revealed a 9.3% increase in revenues to $1.5 billion.

Earnings per share (EPS) was up by an even rosier 12.4% to 20 cents, while NIB's net profit after tax (NPAT) metric rose 12.8% to $91.6 million. This all enabled NIB to jack up its interim dividend by 18.2% to 13 cents per share, fully franked.

Dividend potential

Speaking of dividends, NIB is one of ASX's best companies if you want dividend income from the healthcare sector. For one, the company currently sports a robust trailing dividend yield of 2.9%, which comes fully franked.

That's a fairly decent dividend yield on the ASX today, especially from a healthcare stock. But NIB shares have also shown an ability to increase their dividends over time. We've already noted that this year's interim dividend was a pleasing 18.2% hike over what investors received last year.

It's also important to consider that the 24 cents per share that shareholders bagged in 2021, as well as the 22 cents per share that were paid out in 2022, were massive increases over the 13 cents per share investors got in 2019, and the 14 cents per share doled out in 2020. And back in 2012, shareholders received just 4.3 cents per share.

So the dividends from NIB are certainly going in the right direction.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A stressed businessman sits next to his briefcase with his head in his hands, while the ASX boards behind him show shares crashing.
52-Week Lows

CSL's collapse deepens. Why this ASX giant can't find a floor

CSL shares hit a 9-year low as new demand concerns emerge.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Prediction: CSL shares could surpass $265 in 2026

CSL shares are tumbling again on Wednesday. Here's what it'll take for the price to take a u-turn.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Why are Cochlear shares down 36% today?

The medical device manufacturer has delivered a bitter pill for shareholders.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are ASX healthcare shares the next to rally?

This sector has plenty of opportunity long term.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear cuts FY26 earnings outlook amid softer sales

Cochlear reduces its FY26 earnings guidance amid softer implant sales, ongoing challenges in key markets, and a focus on long-term…

Read more »

A man sits nervously at his computer with his mouth resting against his hands clasped in front of him as he stares at the screen of his computer on a home desk.
Healthcare Shares

EBOS Group trims FY26 earnings guidance as fuel costs bite

EBOS Group trims FY26 earnings guidance as elevated fuel costs weigh on its healthcare distribution businesses.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could more than double Canaccord Genuity says

This company has more than one iron in the fire.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

This ASX biotech's shares just hit a new 12-month high, up more than 700% over a year. Here's why

Good news has this company's shares on the up.

Read more »